Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial. - Wikidata - wikimedia - TriplyDB

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q39304326

about

Lacosamide for neuropathic pain and fibromyalgia in adults Recommendations for the pharmacological management of neuropathic pain: an overview and literature update Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety Lacosamide: what can be expected from the next new antiepileptic drug?The adverse event profile of lacosamide: a systematic review and meta-analysis of randomized controlled trials Lacosamide: a new approach to target voltage-gated sodium currents in epileptic disorders Painful diabetic neuropathy: advantage of novel drugs over old drugs?Recommendations for the definition of clinical responder in insulin preservation studies EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision.Low-dose lacosamide-induced atrial fibrillation: Case analysis with literature review Update on the management of diabetic polyneuropathies.Sodium channel blockers for the treatment of neuropathic pain.Emerging therapies for fibromyalgia: an update.Lacosamide for pain.Emerging drugs for diabetic neuropathy.Pharmacotherapy of epilepsy: newly approved and developmental agents.Pharmacological treatment of diabetic neuropathic pain.Lacosamide in patients with pharmacoresistant epilepsy.Systematic review and meta-analysis of pharmacological therapies for painful diabetic peripheral neuropathy.An investigation of factors contributing to higher levels of placebo response in clinical trials in neuropathic pain: a systematic review and meta-analysis.Emerging drugs for diabetic peripheral neuropathy and neuropathic pain.Fibromyalgia syndrome: novel therapeutic targets.Placebo response in pain, fatigue, and performance: Possible implications for neuromuscular disorders.Efficacy and safety of lacosamide in painful diabetic neuropathy.Post-ictal atrial fibrillation detected during video-EEG monitoring: Case report, proposed physiopathologic mechanism and therapeutic considerations.Sinus node dysfunction: an adverse effect of lacosamide.Analgesic ineffectiveness of lacosamide after spinal nerve ligation and its sodium channel activity in injured neurons.Likert pain score modeling: a Markov integer model and an autoregressive continuous model.Cardiac sodium channel blockade after an intentional ingestion of lacosamide, cyclobenzaprine, and levetiracetam: Case report.Safety and tolerability of lacosamide monotherapy in the elderly: A subgroup analysis from lacosamide trials in diabetic neuropathic pain.

P2860

Q24203727-034E7DE3-507F-4E89-B85D-9E2569F53EFE Q24616897-C013212F-2099-4EB9-8FD2-E84A2CCAE9E0 Q24644936-CF77322E-21EA-419D-A47F-E3E9725704D9 Q24655596-253A8AA8-71A8-4211-B228-80BF658E5B8C Q27026195-6B44F1B3-1BBC-4BBC-87D1-A5399D0A50FB Q28833549-3C628BDB-8A9E-4F24-A721-7CEDCF926CF3 Q33610824-C3EFB655-9606-412C-840E-AA0F68573438 Q34077400-9DC3620D-ABB0-4ED3-AC05-A91F8047E10C Q34110857-2E873CD3-7319-44C3-A569-F6BE9A57D2DB Q34114744-35E7CC5E-D886-4998-BDDF-B5EB2BCE4947 Q35178801-48108BAE-328F-45F5-A3DB-4C5CF5761E32 Q37605350-6C04E818-CDA7-4104-AEDD-50B1DB60A23E Q37756999-FE7EDAEF-52FC-4E53-A998-B4D0D2AABDC9 Q37778066-92AE2D3C-607A-42D9-8EEC-7550CE1FE198 Q37783301-69D7AB49-66C9-48BA-B252-B2A474D8AED2 Q37831297-08F8239B-D879-4B3F-A824-041722D41AB7 Q37858519-5C985B9C-FC74-4763-A9CF-3A2C467D254A Q38032922-AB2FD9F4-DE71-45C3-B091-A0725758C90F Q38093664-281B29D2-F404-45D6-89C0-2C5ACA247D61 Q38307489-87F25E3D-29BF-42DF-B447-F78CD8D96263 Q38798588-3E87E35B-54EB-4A92-AF08-4EB14FD58DC5 Q38863908-0A040D18-B46A-4B7F-B1F1-8BB4CB9871F4 Q38935410-1D822E2D-DC30-45F0-9B43-4179831245DF Q39784392-BF068C3B-5F0C-483B-ABF5-CE00BA650EAA Q41478208-2BC5C692-084F-4A50-B695-F16008328B5C Q44411833-641B2D2C-CDB8-45BE-88B2-726469CFD3A1 Q45363773-B51F662D-F1EE-4122-BB9D-833F491B77CC Q47999794-FC3D6EE3-F995-4906-A014-676F291DCAF5 Q48083617-F014CA7E-2158-4FA4-9B69-641AD824B83C Q55046695-4C8539D3-32E8-42BF-B21C-1C75A19C0D7F

P2860

Lacosamide in painful diabetic neuropathy: an 18-week double-blind placebo-controlled trial.

http://www.wikidata.org/entity/Q39304326

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@en

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@nl

type

label

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@en

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@nl

prefLabel

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@en

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@nl

P1433

Q39304326-EA5C88F8-1786-4DA9-B1CD-15376856F3EE

P1476

Q39304326-7FE26F8B-C984-489A-A95A-32ED1137817C

P2093

Q39304326-127CAA0C-822F-4F0A-9EF9-6F68FD31EEEC

Q39304326-1A925EAC-ABC0-49BA-8F9B-95162E96EFC6

Q39304326-2B10C6EC-8682-4B12-B281-0F67CD104E66

Q39304326-4BDE7DC9-2C77-4C86-AC65-3328663BC46B

Q39304326-549F8B03-CAE7-4BD9-81BA-2CC22C8FFB9D

Q39304326-5D711DE5-DF33-4ABB-8C91-C50E5DEE9F21

Q39304326-B83314AA-14C6-47CB-A854-F65D721C5AB8

P304

Q39304326-A2924FE3-4CA6-450B-8C66-8BEA134ED6BB

P31

Q39304326-3B8B52C0-B8A5-4A33-95EC-08F04860588F

P356

Q39304326-53B15159-595B-4AD4-942F-B193B2219708

P433

Q39304326-ADC62402-1A4A-410E-B521-AF86BB102616

P478

Q39304326-38E255CF-0B2B-4394-A124-918335179715

P577

Q39304326-67E18CC5-83A5-4D90-A34E-7DDE141151BB

P698

Q39304326-8C52E048-00A4-463D-B73E-F57A058AD26D

P921

Q39304326-A633D1B9-9590-4A12-974E-2A886DE2924E

P356

J.JPAIN.2009.01.322

P1433

The Journal of Pain

P1476

Lacosamide in painful diabetic ...... lind placebo-controlled trial.

@en

P2093

Armen Arslanian

http://www.w3.org/2001/XMLSchema#string

Aziz Shaibani

http://www.w3.org/2001/XMLSchema#string

David Sen

http://www.w3.org/2001/XMLSchema#string

Jean-Louis Selam

http://www.w3.org/2001/XMLSchema#string

Jeffrey Simpson

http://www.w3.org/2001/XMLSchema#string

Sabine Bongardt

http://www.w3.org/2001/XMLSchema#string

Salah Fares

http://www.w3.org/2001/XMLSchema#string

P304

818-828

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JPAIN.2009.01.322

http://www.w3.org/2001/XMLSchema#string

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19409861

http://www.w3.org/2001/XMLSchema#string

P921